GRAL
GRAIL, Inc.
$67.19
-0.67
(-0.99%)
Mkt Cap
2.88B
Volume
410,623
52W Range
29.95-118.84
Sector
Healthcare
Beta
3.04
EPS (TTM)
-10.37
P/E Ratio
-7.70
Revenue (TTM)
156.12M
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 147.17M | 125.59M | 93.11M | 55.55M | 14.61M | 0 | 0 | 0 |
| Net Income | (408.35M) | (2.03B) | (1.47B) | (5.40B) | (1.25B) | (312.16M) | (244.85M) | (275.72M) |
| EPS | -11.11 | -63.54 | -47.20 | -173.87 | -40.18 | -2.52 | -1.99 | -2.42 |
| Free Cash Flow | (299.01M) | (582.36M) | (608.69M) | (584.17M) | (758.06M) | (243.91M) | (249.13M) | (225.25M) |
| FCF / Share | -8.14 | -18.26 | -19.60 | -18.81 | -24.41 | -1.97 | -2.02 | -1.97 |
| Operating CF | (299.01M) | (577.16M) | (595.80M) | (561.31M) | (688.13M) | (232.00M) | (245.79M) | (209.26M) |
| Total Assets | 2.92B | 2.98B | 4.56B | 5.60B | 9.74B | 706.30M | 635.52M | 686.85M |
| Total Debt | 98.01M | 68.14M | 84.41M | 96.01M | 110.56M | 62.99M | 42.04M | 2.52M |
| Cash & Equiv | 249.73M | 214.23M | 97.29M | 241.60M | 221.16M | 170.19M | 143.19M | 95.09M |
| Book Value | 2.58B | 2.50B | 3.65B | 4.65B | 9.43B | 561.84M | 550.53M | 600.37M |
| Return on Equity | -0.16 | -0.81 | -0.40 | -1.16 | -0.13 | -0.56 | -0.44 | -0.46 |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 40.78M | 43.60M | 36.19M | 35.54M | 31.84M | 38.25M | 28.65M | 31.97M | 26.72M | 30.33M | 20.72M | 22.41M |
| Net Income | (93.19M) | (99.18M) | (88.98M) | (113.98M) | (106.21M) | (97.07M) | (125.69M) | (1.59B) | (218.91M) | (5.49M) | (891.45M) | (193.04M) |
| EPS | -2.29 | -2.44 | -2.46 | -3.18 | -3.10 | -2.89 | -3.94 | -51.06 | -7.05 | -0.18 | -28.71 | -6.22 |
| Free Cash Flow | (87.49M) | (62.97M) | (63.63M) | (77.33M) | (95.07M) | (93.79M) | (105.55M) | (173.19M) | (209.83M) | (132.79M) | (160.58M) | (141.77M) |
| FCF / Share | -2.15 | -1.55 | -1.76 | -2.21 | -2.77 | -2.94 | -3.31 | -5.58 | -6.76 | -4.28 | -5.17 | -4.57 |
| Operating CF | (86.99M) | (63.78M) | (63.24M) | (76.97M) | (95.01M) | (93.49M) | (104.58M) | (171.80M) | (207.29M) | (128.90M) | (157.51M) | (138.91M) |
| Total Assets | 2.80B | 2.92B | 2.60B | 2.70B | 2.85B | 2.98B | 3.12B | 3.27B | 4.75B | 4.56B | N/A | N/A |
| Total Debt | 51.03M | 98.01M | 58.59M | 62.16M | 64.32M | 68.14M | 72.19M | 76.11M | 79.94M | 84.41M | N/A | N/A |
| Cash & Equiv | 69.34M | 249.73M | 126.89M | 127.43M | 133.90M | 214.23M | 853.55M | 958.85M | 974.10M | 97.29M | N/A | N/A |
| Book Value | 2.50B | 2.58B | 2.24B | 2.31B | 2.41B | 2.50B | 2.59B | 2.70B | 3.99B | 3.65B | N/A | N/A |
| Return on Equity | -0.04 | -0.04 | -0.04 | -0.05 | -0.04 | -0.04 | -0.05 | -0.59 | -0.05 | -0.00 | N/A | N/A |
GRAL News
GRAIL to Present at the 2026 Jefferies Global Healthcare Conference
GRAIL Says Galleri Demand Is Rising as NHS Talks, FDA Review Move Ahead
GRAIL, Inc. (GRAL) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Zaya Younan Unveils the Scientific Holy Grail of Cigar Smoking
GRAIL, Inc. (GRAL) Q1 2026 Earnings Call Transcript
GRAIL Reports First Quarter 2026 Financial Results
GRAIL to Present at the BofA Securities 2026 Health Care Conference
Will Ultragenyx (RARE) Report Negative Q1 Earnings? What You Should Know
GRAIL to Announce First Quarter 2026 Financial Results
GRAIL to Present New Data From NHS-Galleri and PATHFINDER 2 at 2026 ASCO Annual Meeting